Maternal Screening (First Trimester) - Dual Markers with NT Risk Stratification Using Fetal Medicine Foundation (FMF) Method

Maternal Screening (First Trimester) - Dual Markers with NT Risk Stratification Using the Fetal Medicine Foundation (FMF) Method is a prenatal screening assessment used during early pregnancy to estimate the chance that the fetus may have certain chromosomal conditions. It combines two maternal blood markers—pregnancy-associated plasma protein-A, known as PAPP-A, and free beta-human chorionic gonadotropin, known as free beta-hCG—with the fetal nuchal translucency measurement obtained during a first-trimester ultrasound scan.

The screening calculation also considers maternal and pregnancy-related information such as maternal age, gestational age, maternal weight, smoking status, ethnicity, conception method, diabetes status, previous pregnancy history, fetal crown-rump length, and other details required by the validated risk-calculation system. The Fetal Medicine Foundation method combines these variables to produce an individual risk estimate for selected fetal trisomies.

Trisomy is a chromosomal condition in which a fetus has an additional copy of a chromosome. The combined first-trimester screening assessment commonly estimates the probability of trisomy 21, associated with Down syndrome; trisomy 18, associated with Edwards syndrome; and trisomy 13, associated with Patau syndrome. The report expresses risk as a probability, such as 1 in a specified number, rather than providing a definitive positive or negative diagnosis.

This is a screening test and not a diagnostic test. A higher-chance result does not confirm that the fetus has a chromosomal condition, and a lower-chance result cannot exclude every chromosomal or genetic disorder. Pregnant women should discuss the result with their obstetrician, fetal medicine specialist, or genetic counsellor before deciding whether additional testing is appropriate.

Components of First-Trimester Combined Screening

Pregnancy-Associated Plasma Protein-A: PAPP-A is a protein produced mainly by placental tissues during pregnancy. Its concentration normally changes with gestational age. Lower-than-expected levels may be associated with an increased probability of certain chromosomal abnormalities. Low PAPP-A can also be associated with some placental and pregnancy complications, but one result cannot predict an outcome independently.

Free Beta-Human Chorionic Gonadotropin: Free beta-hCG is a component of the pregnancy hormone human chorionic gonadotropin. Its concentration varies throughout pregnancy. In trisomy 21 screening, free beta-hCG may be higher than expected, while lower levels may be observed in pregnancies affected by trisomy 18 or trisomy 13. These patterns are statistical associations and are not individually diagnostic.

Nuchal Translucency Measurement: Nuchal translucency, or NT, is the ultrasound appearance of fluid beneath the skin at the back of the fetal neck. The measurement is performed during a specific gestational window by an appropriately trained sonologist or sonographer. Increased NT may be associated with chromosomal abnormalities, certain structural abnormalities, congenital heart defects, or genetic syndromes. It may also occur in fetuses without an identified abnormality.

Maternal and Pregnancy Information: The FMF calculation adjusts the biochemical marker measurements and combines them with maternal age, gestational age, maternal weight, ethnicity, smoking status, conception method, diabetes status, and other relevant clinical information. Accurate information is essential for a reliable calculation.

Benefits of Dual-Marker Screening with NT and FMF Risk Stratification

• Provides early pregnancy risk assessment for trisomy 21, trisomy 18, and trisomy 13.
• Combines biochemical markers with an ultrasound measurement rather than relying on maternal age alone.
• Uses the FMF methodology to calculate an individual pregnancy-specific probability.
• Can be completed during the first trimester, allowing time for counselling and follow-up decisions.
• Requires only a maternal blood sample and an ultrasound examination.
• Does not create a procedure-related miscarriage risk because the blood test and ultrasound are non-invasive.
• May help identify pregnancies that could benefit from cell-free DNA screening or diagnostic testing.
• Provides PAPP-A and free beta-hCG results as multiples of the median after adjustment for relevant variables.
• Supports informed discussion with an obstetrician, fetal medicine specialist, or genetic counsellor.
• Forms part of comprehensive first-trimester prenatal assessment when performed within the required gestational window.

When Should the Test Be Performed?

The NT scan used for FMF first-trimester screening should generally be performed between 11 weeks and 13 weeks plus 6 days of pregnancy. The fetal crown-rump length should usually be between 45 mm and 84 mm. These requirements help ensure that the NT measurement is performed during the validated screening window.

Maternal blood collection for PAPP-A and free beta-hCG must be coordinated with the ultrasound and laboratory protocol. Depending on the clinical workflow, the blood sample may be collected before, on the same day as, or close to the NT scan. The laboratory requires accurate gestational dating and the ultrasound findings to generate the combined FMF risk estimate.

If the pregnancy is outside the accepted gestational window or an accurate NT measurement cannot be obtained, the combined calculation may not be possible. The obstetrician may then discuss other screening options, such as cell-free DNA-based non-invasive prenatal testing or second-trimester screening, depending on gestational age and clinical circumstances.

Why Doctors Recommend This Screening

Doctors recommend first-trimester combined screening to provide pregnant women and families with early information about the probability of selected common chromosomal conditions. Maternal age alone cannot accurately identify all pregnancies affected by trisomy, because these conditions can occur at any maternal age. Combining maternal age with biochemical markers and NT measurement improves risk estimation.

The FMF approach converts PAPP-A and free beta-hCG concentrations into multiples of the median, commonly abbreviated as MoM. The values are adjusted for relevant maternal and pregnancy characteristics. These adjusted markers are combined with maternal age-related risk and the fetal NT measurement to calculate pregnancy-specific risks.

The screening result may help determine the next step in prenatal care. A lower-chance result may provide reassurance regarding the screened conditions, although it cannot guarantee that the fetus is unaffected. A higher-chance result indicates that further evaluation should be discussed. Options may include genetic counselling, non-invasive prenatal testing using cell-free fetal DNA, chorionic villus sampling, or amniocentesis.

Cell-free DNA screening is a more sensitive screening method for common trisomies, but it is still not diagnostic. Chorionic villus sampling and amniocentesis are diagnostic procedures that can examine fetal or placental genetic material. These procedures have specific benefits, limitations, timing requirements, and risks that should be discussed with a qualified specialist.

Preparation Before the Test

Fasting is generally not required for the dual-marker blood test. The pregnant woman may usually eat, drink, and take prescribed medicines normally unless the obstetrician or laboratory provides different instructions.

Bring the referring doctor's request, identification details, pregnancy ultrasound report, NT measurement, fetal crown-rump length, gestational age, and expected date of delivery. The laboratory may also request maternal date of birth, current weight, ethnicity, smoking status, diabetes status, conception method, number of fetuses, and previous pregnancy history.

Inform the laboratory whether the pregnancy was conceived naturally or through assisted reproductive technology, including in vitro fertilisation. For assisted pregnancies, information regarding embryo transfer, egg collection, donor egg use, and the age of the egg donor may be required. These details may affect the risk calculation.

Tell the laboratory if the pregnancy involves twins or more than one fetus. Multiple pregnancies require different calculation methods, and screening performance and interpretation differ from singleton pregnancy. Information about chorionicity may be necessary.

Ensure that all names, dates, measurements, and pregnancy information are accurate. Incorrect maternal weight, gestational age, fetal crown-rump length, NT measurement, or conception details can alter the calculated risk.

What Happens During the Test?

A trained phlebotomist collects a small blood sample from a vein in the pregnant woman's arm. The sample is processed to measure PAPP-A and free beta-hCG concentrations. The blood collection usually takes only a few minutes and poses no direct risk to the fetus.

The NT ultrasound is a separate non-invasive examination. During the scan, the sonologist or trained sonographer confirms fetal viability, measures the fetal crown-rump length, and assesses the nuchal translucency. Accurate NT measurement requires an appropriate fetal position, a correct mid-sagittal view, proper magnification, and careful placement of measurement callipers.

The laboratory converts the biochemical measurements into adjusted MoM values and combines them with the NT measurement and maternal information using the FMF risk-calculation methodology. The final report provides individual risk estimates for the screened chromosomal conditions.

The blood collection may cause brief discomfort, mild bruising, or tenderness at the needle site. Serious complications are uncommon. The NT ultrasound uses sound waves and does not involve ionising radiation.

Normal Reporting Time

The report for Maternal Screening (First Trimester) - Dual Markers with NT Risk Stratification Using the FMF Method is generally available within 3 to 5 working days after the laboratory receives the blood sample, complete NT scan measurements, and all required maternal information.

Reporting may be delayed if essential clinical details are missing, gestational dating is unclear, the NT measurement is unavailable, the pregnancy involves multiple fetuses, or repeat biochemical analysis is required. Patients should confirm the expected turnaround time with Focus Diagnostics when submitting the sample.

Who Should Consider This Screening?

• Pregnant women between 11 weeks and 13 weeks plus 6 days of gestation.
• Women seeking early screening for trisomy 21, trisomy 18, and trisomy 13.
• Pregnant women of any maternal age after counselling with their obstetrician.
• Women with an NT scan performed within the validated FMF measurement window.
• Pregnancies conceived naturally or through assisted reproductive technology.
• Women with a previous pregnancy affected by a chromosomal condition.
• Pregnant women with a family or medical history requiring prenatal risk assessment.
• Women who want a non-invasive first-trimester screening assessment before considering further testing.
• Patients referred by an obstetrician, fetal medicine specialist, or genetic counsellor.
• Women who understand the benefits and limitations of screening and provide informed consent.

Understanding the Screening Report

The report includes the measured concentrations of PAPP-A and free beta-hCG, their adjusted MoM values, the fetal NT measurement, and calculated risks for selected trisomies. Risk may be expressed as 1 in a number. For example, a result of 1 in 100 represents a greater estimated chance than a result of 1 in 1,000.

Lower-Chance Result: A result below the programme's high-risk threshold means that the calculated probability of the screened condition is lower. It does not guarantee that the fetus does not have trisomy 21, trisomy 18, trisomy 13, another chromosomal condition, a genetic syndrome, or a structural abnormality.

Higher-Chance Result: A result above the screening threshold means that the calculated probability is increased. It is not a diagnosis and does not mean that the fetus definitely has the condition. Many pregnancies with a higher-chance screening result will not be affected.

The threshold used to classify results may vary according to clinical programme, laboratory policy, and local medical guidance. The obstetrician should interpret the reported probability rather than relying only on labels such as low risk or high risk.

After a higher-chance result, the doctor may discuss detailed ultrasound assessment, genetic counselling, non-invasive prenatal testing, chorionic villus sampling, or amniocentesis. The appropriate choice depends on gestational age, ultrasound findings, personal preferences, previous history, and the level of diagnostic certainty desired.

An increased NT measurement may require specialist evaluation even if the calculated trisomy risk is not high. Increased NT can be associated with structural abnormalities, congenital heart defects, or genetic syndromes. A fetal medicine specialist may recommend additional ultrasound examinations, fetal echocardiography, diagnostic genetic testing, or follow-up according to the individual findings.

Clinical Limitations

This assessment is a screening test and cannot confirm or exclude a fetal chromosomal condition. False-positive and false-negative results can occur. Screening performance depends on correct gestational dating, accurate NT measurement, reliable biochemical analysis, complete maternal information, and appropriate risk calculation.

The test primarily evaluates the probability of the chromosomal conditions included in the report. It does not screen for every chromosome abnormality, single-gene condition, birth defect, developmental condition, or pregnancy complication.

The blood markers can be affected by gestational age, maternal weight, ethnicity, smoking, diabetes, conception method, multiple pregnancy, and other biological variables. The FMF method adjusts for several of these factors, but accurate patient information is necessary.

A lower-chance result does not replace routine antenatal care, the recommended fetal anomaly scan, or other investigations advised by the obstetrician. A higher-chance result should not be used alone to make irreversible pregnancy decisions. Diagnostic confirmation and specialist counselling should be discussed.

Important Safety Information

Pregnant women should review the result with their obstetrician or fetal medicine specialist. Do not interpret an abnormal PAPP-A, free beta-hCG, NT, or risk value in isolation. The combined pattern and complete pregnancy assessment are clinically important.

Seek urgent obstetric care for heavy vaginal bleeding, severe abdominal pain, fluid leakage, fainting, fever, or other concerning pregnancy symptoms. This screening test does not evaluate obstetric emergencies.

This information is intended for general education and does not replace prenatal counselling, ultrasound assessment, diagnosis, or advice from an obstetrician, fetal medicine specialist, or genetic counsellor.